REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
612.49 USD   +0.84%
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Transthyretin Amyloidosis
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis

05/20/2022 | 03:46pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 0.84% 612.49 Delayed Quote.-3.01%
SANOFI 5.02% 100.56 Real-time Quote.13.52%
All news about REGENERON PHARMACEUTICALS, INC.
06/24SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Friday
MT
06/24SECTOR UPDATE : Health Care
MT
06/24Intellia Therapeutics, Regeneron Report Positive Data From NTLA-2001 Study to Treat Tra..
MT
06/24Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based ..
AQ
06/15REGENERON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (for..
AQ
06/14TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global ..
CI
06/14RBC Cuts Price Target on Regeneron Pharmaceuticals to $647 From $658, Noting Risk to Ey..
MT
06/09Alnylam Pharmaceuticals Says Cemdisiran Product Meets Primary Endpoint of Immunoglobuli..
MT
06/09ALNYLAM : Encouraging Results From Phase 2 Cemdisiran Study in IgA Nephropathy
DJ
06/08Regeneron Pharmaceuticals, Inc. - FDA APPROVES DUPIXENT (DUPILUMAB) AS FIRST BIOLOGIC M..
AQ
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 11 756 M - -
Net income 2022 4 039 M - -
Net cash 2022 8 626 M - -
P/E ratio 2022 16,8x
Yield 2022 -
Capitalization 65 993 M 65 993 M -
EV / Sales 2022 4,88x
EV / Sales 2023 4,28x
Nbr of Employees 10 492
Free-Float 81,0%
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 612,49 $
Average target price 679,24 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
GILEAD SCIENCES, INC.-13.12%77 153
VERTEX PHARMACEUTICALS33.22%69 645
WUXI APPTEC CO., LTD.-13.42%41 016
BIONTECH SE-48.69%30 052
GENMAB A/S-17.76%19 922